GLMD
Galmed Pharmaceuticals Ltd.·Healthcare
0.74
5.629%(−0.04)
Market ClosedLast Updated: — ET
52W L: $0.4152W H: $2.68
GLMD NEWS
benzinga.com
2d ago
Galmed Stock Soars On Brain-Penetrating Aramchol Formulation
Galmed said it developed a new formulation of its SCD1 inhibitor, Aramchol, designed to cross the blood-brain barrier and target central nervous system diseases.
prnewswire.com
2d ago
Galmed Announces the Breakthrough Development of a Brain Penetrating New Formulation of its SCD1 inhibitor, Aramchol
98% of drugs do not reach the brain, as the blood–brain barrier (BBB) separates peripheral blood circulation from the central nervous system (CNS). Galmed has developed, in collaboration with Barcode Nanotech, a unique proprietary formulation of Aramchol which targets the brain.
prnewswire.com
Mar 31
Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2025
TEL AVIV, Israel, March 31, 2026 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, cardiometabolic diseases and GI oncological therapeutics, today announced that it has filed its Annual Report on Form 20-F for the fiscal year ended December 31, 2025, with the U.S. Securities and Exchange Commission (the 'SEC').
defenseworld.net
Feb 14
Surrozen (NASDAQ:SRZN) & Galmed Pharmaceuticals (NASDAQ:GLMD) Financial Review
Surrozen (NASDAQ: SRZN - Get Free Report) and Galmed Pharmaceuticals (NASDAQ: GLMD - Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, earnings, valuation and risk. Institutional and Insider Ownership 66.6% of Surrozen shares
defenseworld.net
Feb 2
Short Interest in Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Decreases By 15.8%
Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD - Get Free Report) was the recipient of a large decrease in short interest during the month of January. As of January 15th, there was short interest totaling 61,515 shares, a decrease of 15.8% from the December 31st total of 73,076 shares. Currently, 4.6% of the shares of the stock are
prnewswire.com
Jan 30
Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification
TEL AVIV, Israel, Jan. 30, 2026 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, cardiometabolic diseases and GI oncological therapeutics, today announced that the Company received a letter from the Nasdaq Listing Qualifications (the "Letter"), indicating that the Company is not in compliance with the minimum bid price requirement for continued listing set forth in Listing Rule 5550(a)(2), which requires listed securities to maintain a minimum bid price of $1.00 per share.
